The up-rise in e-cigarette use - friend or foe?

Respiratory Research

Volumn 17, Issue 1, 2016, Pages

  Lundbäck, Bo ^a   Katsaounou, Paraskevi ^b   Lötvall, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CD11B ANTIGEN; CD66B ANTIGEN; CIGARETTE SMOKE; LYMPHOCYTE ANTIGEN; NICOTINE; NITRIC OXIDE; UNCLASSIFIED DRUG; VARENICLINE;

AIRWAY; AIRWAY RESISTANCE; CARCINOGENICITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COUNSELING; EDITORIAL; ELECTRONIC CIGARETTE; ELECTRONIC CIGARETTE VAPOR EXTRACT; EXPOSURE; HEALTH HAZARD; HUMAN; IMPEDANCE; INFLAMMATION; MEDICAL INFORMATION; NEUTROPHIL; NONHUMAN; PRIMARY PREVENTION; PUBLIC HEALTH; RISK REDUCTION; SAFETY; SECONDARY PREVENTION; SMOKING CESSATION; TOBACCO DEPENDENCE; TRAINING; ADOLESCENT; ADULT; FEMALE; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84977586637     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-016-0371-2     Document Type: Editorial

References (24)

1. Gibson J, Loddenkemper R, Sibille Y, Lundbäck B. The European Lung White Book. Sheffield: the European Respiratory Society; 2013.
2. Omaima I Abo-Elkheir OI, Sobh E. Knowledge about electronic cigarettes and its perception: a community survey, Egypt. Respir Res. 2016. In press.
3. McNeill A, Brose LS, Calder R, et al. E-cigarettes: an evidence update: a report commissioned by Public Health England. Public Health England. 2015.
4. McKee M, Capewell S. Evidence about electronic cigarettes: a foundation built on rock or sand? BMJ. 2015;351:h4863.
5. E-cigarettes: Public Health England's evidence-based confusion. Editorial. Lancet. 2015;386(9996):829.
6. Vardavas CI, Filippidis FT, Agaku IT. Determinants and prevalence of e-cigarette use throughout the European Union: a secondary analysis of 26 566 youth and adults from 27 Countries. Tob Control. 2015;24(5):442-8.
7. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016 (E-pub January 16).
8. Sherratt FC, Newson L. Electronic cigarettes: a survey of perceived patient use and attitudes among members of The British Thoracic Oncology Group. Respir Res. 2016.
9. McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. The Cohrane Collaboration. 2014.
10. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382(9905):1629-37.
11. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8(6):e66317.
12. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;31:5.
13. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:CD008286.
14. Gonzales D, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
15. Jorenby DE et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
16. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004;23:327-33.
17. Goniewicz ML, Knysak J, Gawron M, Kosmider L, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23:133-9.
18. Franck C, Filion KB, Kimmelman J, Grad R, Eisenberg M. Ethical considerations of e-cigarette use for tobacco harm reduction. Respir Res. 2016.
19. Bahl V, Lin S, Xu N, Davis B, Wang YH, Talbot P. Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod Toxicol. 2012;34:529-37.
20. Cara L. Sherwood CL, Boitano S. Airway epithelial cell exposure to distinct e-cigarette liquid flavorings reveals toxicity thresholds and activation of CFTR by the chocolate flavoring 2,5-dimethypyrazine. Respir Res. 2016.
21. Higham A, Rattray NJW, Dewhurst JA, Trivedi D, et al. Electronic Cigarette Exposure Triggers Neutrophil Inflammatory Responses. Respir Res. 2016.
22. Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest. 2012;141:1400-6.
23. Durmowicz EL. The impact of electronic cigarettes on the paediatric population. Tob Control. 2014;23(S2):41-6.
24. Schraufnage DE, Blasi F, Drummond MB, Lam DC, et al. Electronic Cigarettes: a position statement of the Forum of International Respiratory Societies. Am J Respir Crit Care Med. 2014;190(6):611-8.